Flubromazepam

Flubromazepam is a synthetic 1,4-benzodiazepine related to phenazepam. It was first prepared in the early 1960s but was not developed into a medicine. The compound reappeared on the research-chemical market in the 2010s and is known for its long-lasting central nervous system depressant effects. Its elimination half-life has been estimated at around 100 hours, although clinical data remain limited.

Chemistry and history

Flubromazepam contains a bromine atom on the benzodiazepine ring and a fluorinated phenyl group. Its structure is related to phenazepam, with fluorine and bromine substituents in place of the corresponding halogen pattern. It is a conventional 1,4-benzodiazepine rather than a triazolobenzodiazepine.

Although the compound was synthesised in the early 1960s, it attracted little attention until it was identified in seized capsules in Germany in 2013. It has since appeared in powders, capsules, tablets and other products sold as research chemicals.

Pharmacology and metabolism

Like other benzodiazepines, flubromazepam acts as a positive allosteric modulator at the GABA_A receptor. It enhances the inhibitory effect of GABA, producing anxiolytic, sedative, hypnotic and muscle-relaxant effects. Direct pharmacodynamic studies are limited, and its receptor profile has not been mapped in detail.

Flubromazepam is lipophilic and highly protein-bound. Human and laboratory analyses have identified hydroxylated and debrominated metabolites, as well as glucuronide conjugates. Pharmacokinetic studies have reported an elimination half-life of approximately 100–106 hours. This unusually long persistence can lead to accumulation and prolonged impairment, particularly with repeated exposure (WHO critical review, 2023).

Subjective effects

The PsychonautWiki profile of flubromazepam describes long-lasting benzodiazepine effects. Information about its psychological effects still comes mainly from users rather than controlled clinical trials.

Physical effects

Reported effects include relaxation, muscle relaxation and sedation. Some users describe a gradual onset and a prolonged period of drowsiness. More intense effects may include confusion, impaired coordination and marked sleepiness.

Cognitive and emotional effects

Online reports describe reduced anxiety, euphoria, increased confidence and, in some accounts, empathy. Confusion and amnesia are also reported. The combination of long persistence and memory impairment can make it difficult to recognise when the effects have fully resolved.

Clinical and forensic findings

Flubromazepam has been detected in post-mortem blood samples and impaired-driving investigations in several countries. In many cases, other drugs were also present, so its individual contribution could not be established. The WHO review describes reports of severe central nervous system depression and notes that the available human data are insufficient to determine a precise relationship between blood concentration and impairment.

A 2026 clinical case report described prolonged coma and multifocal cerebral ischaemia in a patient with flubromazepam exposure. The authors considered the substance a likely explanation after other causes had been investigated. The case illustrates the potential for serious toxicity, but a single report cannot define the frequency of such outcomes (Flubromazepam intoxication causing prolonged coma, 2026).

Dependence and safety

There are no controlled human studies of flubromazepam dependence. User reports describe tolerance and withdrawal, but these accounts have not been systematically confirmed. Its long elimination time may prolong intoxication and increase the chance of accumulation.

As with other benzodiazepines, combining flubromazepam with opioids, alcohol or other sedatives can increase central nervous system depression. Abrupt cessation after regular use may cause severe withdrawal, including seizures, and should be managed with medical support.

Related compounds

Flubromazepam is related to Phenazepam and Flubromazolam. The latter is a triazolo derivative with a different structure and a separate pharmacological profile; the two substances should not be confused.